Eiger BioPharmaceuticals, Inc. Gains 27.98%
Fri, Jun 30, 2023 at 07:58 PM
Eiger BioPharmaceuticals, Inc. (EIGR:NASDAQ) rocketted at $0.7, representing a gain of 28%. The stock appeared on our News Catalysts scanner on Thu, Jun 29, 2023 at 12:04 PM in the 'MISCELLANEOUS' category. From Fri, Jun 16, 2023, the stock recorded 11.11% Up Days and 10.00% Green Days
The stock spiked on Thu, Feb 09, 2023 at $2.98 with a volume of 9M+.
About Eiger BioPharmaceuticals, Inc. (EIGR:NASDAQ)
Eiger BioPharmaceuticals Inc is a clinical stage biopharmaceutical company. It is focused on bringing to market novel product candidates for the treatment of orphan diseases.
Top 10 Gainers:
- Viveve Medical, Inc. (VIVE:NASDAQ), 2900%
- Baudax Bio, Inc. (BXRX:NASDAQ), 124.91%
- VBI Vaccines Inc. (VBIV:NASDAQ), 75%
- Renalytix AI plc (RNLX:NASDAQ), 43.84%
- CymaBay Therapeutics, Inc. (CBAY:NASDAQ), 39.67%
- Rackspace Technology Inc. (RXT:NASDAQ), 38.78%
- Cyteir Therapeutics Inc. (CYT:NASDAQ), 35.42%
- Eiger BioPharmaceuticals, Inc. (EIGR:NASDAQ), 27.98%
- PainReform Ltd. (PRFX:NASDAQ), 27.06%
- Gracell Biotechnologies Inc. (GRCL:NASDAQ), 27%